Table 2.

Gating results extracted from the treatment delivery of the 10 OSS patients. The dose was delivered in two consecutive parts, during which patient tolerance was assessed.

Patient	ROI (%)	GTV ∩ Boundary	GTV ∩ PTV	Latency Effect	Duty-Cycle	% Frames Latency
	Part1/Part2	5th–95th	5th–95th	Mean(%)	(%)	ON-OFF/OFF-ON
1	10/10	85.7–100	96.4–100	−0.5	43.3	7.8/4.7
2	10/10	87.9–100	100–100	−0.2	57.3	12.5/5.2
3	10/10	89.2–100	99.0–100	−0.2	64.7	18.1/8.2
4	15/15	80.0–100	97.8–100	−0.5	40.8	11.7/8.2
5	10/10	91.1–100	100–100	0.0	43.8	4.2/2.2
6	10/10	78.0–100	94.4–100	−0.8	35.6	7.6/5.6
7	10/10	89.1–100	96.2–100	−0.4	51.5	13.0/5.8
8	10/10	90.8–100	99.2–100	−0.2	41.3	5.3/2.8
9	10/7	93.1–100	99.8–100	−0.1	39.8	7.0/4.3
10	10/15	83.1–100	98.5–100	−0.5	26.1	8.6/5.9

ROI(%): threshold used to trigger automatic beam-off when the GTV is outside the Boundary. For the majority of patients a threshold of 10% was used. To increase the efficiency, for two patients a threshold of 15% was used.

GTV ∩ Boundary/PTV: amount of overlap between the GTV and Boundary/PTV during beam-on.

Latency Effect: mean decrease in the overlap of GTV with Boundary/PTV as a result of beam latency (Gating Off/Beam On).

Duty-Cycle: efficiency during treatment delivery (ratio of beam-on time to total time).

% Frames latency: percentage of frames affected by beam latency (Gating On/Beam Off, and Gating Off/ Beam On).